Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; therapeutic vaccine and prophylactic for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission; and VL-2397 antifungal, which is in Phase 1, for the treatment of fungal infections. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.